Abstract: The present invention relates to a nucleic acid molecule encoding (I) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of SEQ ID NO: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein T is replaced by U; (II) a fragment of the polypeptide of (I) having the activity of an endonuclease.

Abstract: An imaging apparatus (100) for imaging an object (1) under investigation, in particular a biological object, comprises a light source device (10) arranged for an illumination of the object (1), a light detector device (20) arranged for detection of light emitted by the object (1) in response to the illumination of the object (1), an acoustic detector device (30) arranged for collecting acoustic signals generated in the object (1) in response to the illumination of the object (1), an image reconstruction device (40) arranged for reconstructing an optical image and an opto-acoustic image of the object (1), and a resolution adaptation device (50) being capable of adjusting imaging properties of the opto-acoustic image, said imaging properties including at least one of the spatial resolution and the imaging depth of the opto-acoustic image. Furthermore, an imaging method for imaging an object (1) under investigation, in particular a biological object, is described.

Abstract: An ultrasound detector adapted for ultrasound detection with medical applications includes an optical waveguide, and at least one Bragg grating, created with a predetermined refractive index modulation amplitude in the optical waveguide, wherein the at least one Bragg grating includes a localized defect in periodicity so that a localized-light resonance portion is formed around the defect, and the localized-light resonance portion has spectral properties capable of being modulated in response to an ultrasound oscillation, wherein the optical waveguide is a non-amplifying optical medium, and the refractive index modulation amplitude is selected such that the localized-light resonance portion is concentrated at the defect in periodicity and the ultrasound oscillation can be sensed by the at least one Bragg grating with an acoustic sensitivity most of which being obtained over the localized-light resonance portion.

Abstract: An imaging device for medical imaging includes a light source device arranged to illuminate a sample under investigation with illumination light, a detector device arranged to collect a plurality of images including at least two sample light images backscattered by the sample in different spectral ranges, and at least one marker light image originating from at least one marker substance in the sample, and a processor device adapted to process the at least two sample light images and create at least one correction component, the processor device further adapted to correct the marker light image using the at least one correction component.

Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.

Abstract: The present invention relates to the (S)-enantiomer of mepazine, its applicability in therapy, a pharmacological composition comprising (S)-mepazine, and processes for the preparation of (S)-mepazine and one of its intermediates.

Abstract: The present invention relates to a nucleic acid molecule encoding (I) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of SEQ ID NO: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein T is replaced by U; (II) a fragment of the polypeptide of (I) having the activity of an endonuclease.

Abstract: The present invention relates to the use of the biomarker Flattop (Fltp) for distinguishing mature ? cells from immature progenitor ? cells. The present invention further relates to a method for distinguishing a mature ? cell from an immature progenitor ? cell, the method comprising: determining the presence or absence of the biomarker Flattop (Fltp) in a ? cell; wherein the presence of Fltp in the cell indicates that the cell is a mature ? cell and wherein the absence of Fltp in the cell indicates that the cell is an immature progenitor ? cell. Furthermore, the present invention relates to a method of identifying a compound suitable for differentiating immature progenitor ? cells into mature ? cells as well as to a method of identifying a compound suitable for preventing the de-differentiating of mature ? cells.

Abstract: The present invention relates to semi-allogeneic antigen-presenting cells into which proteins and/or peptides or RNA or DNA or cDNA, respectively, encoding said proteins and/or peptides which are overexpressed in tumor cells or which are derived from autologous tumor cells or different tumor cells or different tumor cell lines have been introduced. Furthermore the invention relates to methods for the generation of these semi-allogeneic antigen-presenting cells as well as to the use thereof in the treatment of tumor diseases.

Abstract: A method of multi-spectral opto-acoustic tomography (MSOT) imaging of a target tissue including a target tissue biomarker includes illuminating the target tissue with an illumination device emitting at least one pulsed illumination pattern at several illumination wavelengths, detecting pressure signals from the target tissue biomarker with a detector device, wherein the pressure signals being produced in the target tissue are in response to the illumination, and reconstructing a quantitative tomographic image of a distribution of the target tissue biomarker in the target tissue, wherein the pressure signals are analyzed using a photon propagation model which depends on an illuminating light fluence in the target tissue and on the illumination wavelengths, at least one spectral processing scheme, and an inversion scheme providing the tomographic image.

Abstract: The invention relates to a method for in vitro maturation of at least one immate dendritic cell, comprising stimulating said immature dendritic cell with TNF?, IL-1?, IFN?, a TLR7/8 agonist and prostaglandin E2(PG). Furthermore, the invention elates to a composition comprising these factors as well as to mature dendritic cells produced by a method of the invention.

Abstract: The disclosure relates to systems and methods for optoacoustic imaging of an object comprising, in some embodiments, an image acquisition unit for acquiring a first sequence of tomographic optoacoustic images, the image acquisition unit comprising an illumination device and a detection device configured for repeatedly collecting acoustic waves emerging from the object and for generating the first sequence of tomographic optoacoustic images. In some embodiments, a processing unit is provided for generating a second sequence of one or more tomographic optoacoustic images from the first sequence of tomographic optoacoustic images based on an analysis of one or more tomographic optoacoustic images of the first sequence of tomographic optoacoustic images and/or at least one property of the object while acquiring the first sequence of tomographic optoacoustic images and/or at least one property of the acquisition unit while acquiring the first sequence of tomographic optoacoustic images.

Abstract: The present invention relates to a method of identifying a predisposition for developing type 2 diabetes mellitus in a subject, said method comprising the step of assessing in a sample obtained from said subject the amount of one or more metabolite(s) selected from (a) a first group comprising the metabolites glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2, phosphatidylcholine acyl-alkyl C36:3 and isobaric metabolites having the same molecular mass as glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2 or phosphatidylcholine acyl-alkyl C36:3 but different chemical formula; and/or (b) a second group comprising the metabolite acetylcarnitine C2 and an isobaric m

Abstract: The present invention comprises methods and compositions related to trans-differentiating differentiated cells, the methods comprising bringing said cells into contact with a polypeptide or a nucleic acid encoding said polypeptide.

Abstract: The invention relates to a method for in vitro maturation of at least one immate dendritic cell, comprising stimulating said immature dendritic cell with TNF?, IL-1?, IFN?, a TLR7/8 agonist and prostaglandin E2(PG). Furthermore, the invention elates to a composition comprising these factors as well as to mature dendritic cells produced by a method of the invention.

Abstract: The invention relates to a method for operating an electronic terminal (1.1-1.4) comprising an integrated image sensor (2.1-2.4) that has a large number of pixels, in particular for a mobile telephone. According to the invention, a dosage value of ionizing radiation striking the image sensor is determined by means of the image sensor (2.1-2.4). The invention further relates to a terminal that operates accordingly (e.g. a smart phone having a corresponding application program).

Abstract: The invention relates to a compound for use in treating a cancer, wherein the cancer depends on the proteolytic activity of the MALT1 protease, and wherein the compound has the general formula (I) wherein X is N or C; Y is S, O, SO2, SO, NH, CO, CH2, CH?CH, or CH2—CH2; ( )z is a C1-C5 linear or branched alkyl chain; A is NR3R4, or OR5, or HET; R1 and R2 in each occurrence are independently selected from —H, —CH3, —OH, —OCH3, —SCH3, —F, —Cl, —CF3, —NH2, and —COOH; R3, R4, and R5 are H, or C1-C5 linear or branched alkyl groups, and HET is a heterocyclic ring of 5, 6, or 7 members, wherein the ring atoms can be C, O, N, or S, the ring can be saturated or aromatic, and the ring can be substituted with H or C1-C5 linear or branched alkyl groups; or a pharmaceutically acceptable salt, prodrug, enantiomer, diastereomer, racemic mixture, crystalline form, amorphous form, unsolvated form or solvate of said compound.

Abstract: The present invention relates to a method of producing a modified protein having an increased stability and/or improved folding efficiency as compared to the unmodified protein, the method comprising (i) modifying a nucleic acid molecule encoding a protein comprising at least one immunoglobulin constant domain-like region by (a-i) replacing the nucleotides encoding at least one amino acid, preferably an uncharged amino acid, in the loop separating the C strand from the D strand with nucleotides encoding a charged amino acid selected from the group consisting of Arg, Lys, His, Glu and Asp and/or replacing the nucleotides encoding at least one amino acid, preferably an uncharged amino acid, in the helix connecting the E strand with the F strand with nucleotides encoding a charged amino acid selected from the group consisting of Arg, Lys, His, Glu and Asp; (a-ii) replacing the nucleotides encoding at least one amino acid not having a side chain that can form a hydrogen bond in the loop separating the C strand fr

Abstract: The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin.

Abstract: A system for creating an object image of an object under investigation, comprises a computing device being configured for creating the object image by using first tomography data of the object provided by a first tomography system and second tomography data of the object provided by a second tomography system, wherein the computing device is configured for calculating a first forward model describing the first tomography data using the second tomography data, performing a first inversion of the first forward model, calculating a parameter set using the first inversion, and performing a second inversion using the parameter set to obtain the object image to be created. Furthermore, a method of imaging an object under investigation is described, wherein the system for creating an object image is used.